CCXI ChemoCentryx, Inc.

7.07
-0.01  -0%
Previous Close 7.08
Open 7.08
Price To book 7.36
Market Cap 340.58M
Shares 48,173,000
Volume 79,483
Short Ratio 18.06
Av. Daily Volume 104,058

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Partner required to continue with Phase 3 program
Vercirnon CCX282
Crohn's disease
Phase 2 top-line data released Dec 12 2014. Partner required for further development.
CCX140
Diabetic nephropathy
Phase 1b early response data released September 1, 2016. Initial PFS data released January 20, 2017.
CCX872
Non-resectable pancreatic cancer
Phase 2 data presented at ASN Kidney Week - November 17, 2016.
CCX168
Atypical Hemolytic Uremic Syndrome (aHUS)
Phase 3 initiated December 2016.
CCX168 (ADVOCATE)
Associated vasculitis (AAV)

Latest News

  1. ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G)
  2. Edited Transcript of CCXI earnings conference call or presentation 10-May-17 9:00pm GMT
  3. ChemoCentryx, Inc. – Value Analysis (NASDAQ:CCXI) : May 15, 2017
  4. ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : May 12, 2017
  5. ChemoCentryx reports 1Q loss
  6. ChemoCentryx Reports First Quarter 2017 Financial Results
  7. Investor Network: Chemocentryx, Inc. to Host Earnings Call
  8. ChemoCentryx to Hold First Quarter 2017 Financial Results Conference Call on Wednesday, May 10, 2017
  9. ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : April 6, 2017
  10. ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G)
  11. ChemoCentryx (CCXI) Shares March Higher, Can It Continue?
  12. Edited Transcript of CCXI earnings conference call or presentation 14-Mar-17 9:00pm GMT
  13. ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results
  14. Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix
  15. Sio Capital Remains Bullish On These Stocks Despite Weak Performance
  16. ChemoCentryx to Hold Fourth Quarter 2016 Financial Results Conference Call on Tuesday, March 14, 2017
  17. ChemoCentryx to Present at the Cowen and Company 37th Annual Health Care Conference